A blood component separation device for separating a plurality of blood components from blood sampled from a blood donor, and collecting platelets, includes: an operation unit that calculates a predicted platelet recovery rate from a hematocrit value of the blood and a platelet concentration of the blood, and calculates a recommended processing amount of the blood recommended for collecting a target number of units of platelets on the basis of the calculated predicted platelet recovery rate, wherein the operating unit sets the predicted platelet recovery rate calculated from any the hematocrit value and any the platelet concentration to be smaller by a predetermined value a when the blood donor is female than that when the blood donor is male.

The invention relates to a system for platelet release from a fluid comprising in particular megakaryocytic cells comprising cytoplasmic extensions.

The system allows to reproduce the pipetting process performed manually by means of a pipette, thereby permitting a continuous and automatic release of platelets.

This is performed on a large scale since the geometry of the system according to the invention allows to treat large volumes of fluid with a high flow rate (of the order of a plurality of liters per hour), thereby making it particularly suitable for use on an industrial scale.

The invention also relates to a method for platelet release from a fluid comprising in particular megakaryocytic cells comprising cytoplasmic extensions, said method being implemented by means of the abovementioned system.

Methods and systems for transfusing reduced-volume blood components are disclosed. Previously collected blood components are introduced into a fluid circuit associated with an apparatus that further separates the component into a reduced volume component and supernatant. The reduced-volume blood component is transfused to the patient in need of the component without the risk of circulatory overload.

The present invention may include an upper cap having an opening/closing member for opening and closing an inlet through which a blood is injected; a main body housing having an open upper end outer surface thereof assembled with the upper cap, and having an inner space in which the blood is filled with; an adjustment housing that is coupled to the main body housing to seal the open lower end of the main body housing, and is movably assembled with respect to the main body housing so that a buffy coat layer is positioned on a neck portion; and a side cap fixed to the neck portion by forming a needle hole through which an end of an injection needle for extraction enters and exits in area corresponding to a sealing member to seal an extraction hole formed through the neck portion.

The present disclosure provides compositions and methods for managing female infertility, caused by reduced thickness and receptivity of the endometrial lining. More particularly, the present disclosure provides a platelet derived growth factor concentrate and a composition comprising the same, preferably in combination with a stimulus responsive polymer. Consequently, methods to obtain the said compositions, along with therapeutic applications in improvement in thickness and receptivity of the endometrial lining are provided.

Apparatus and methods for concentrating platelet-rich plasma is described herein. One variation may generally comprise a tube having a length and defining a channel within and one or more ports located at a proximal end of the tube and in fluid communication with the channel. A plunger may slidably translatable within the channel while forming a seal against an inner surface of the channel and a float may have a pre-selected density and defining a concave interface surface, wherein the float is slidably contained within the channel such that the concave interface surface is in apposition to the one or more ports.

This invention relates in general to the field of cell-therapy treatments and more particularly, but not by way of limitation, to systems and methods for administering personalized cell-therapy treatments intravenously. In various embodiments, the system may calculate an aspiration volume needed for centrifugation to achieve a concentrated target threshold dose of 2×10.sup.6 platelets/μL for a particular cell therapy using various factors such as, for example, information about a patient and the efficiency of the concentration process.

Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogenic settings.

The disclosure provides for a container system and method for the cryopreservation and resuspension of a body fluid. The container system may include a cryopreservation container comprising the body fluid in a cryopreservation liquid, a resuspension container comprising a resuspension solution, a connection tube sterilely connecting the cryopreservation container and the resuspension container, and at least one shut-off element actively associated with the connection tube.

Systems and methods are provided for depleting platelets from blood. The system includes a multi-stage blood separation chamber in which blood is separated into red blood cells and platelet-rich plasma. The platelet-rich plasma is conveyed from a first stage of the chamber to a second stage, where it is separated into platelets and platelet-poor plasma. The platelet-poor plasma is conveyed out of the chamber while the platelets are allowed to accumulate in the second stage of the chamber. When a controller of the system has determined that the maximum chamber capacity of platelets has been accumulated in the second stage of the chamber, the platelets are conveyed out of the chamber to a waste container. The cycle of separating blood into its components, accumulating platelets in the chamber, and then flushing the platelets from the chamber is repeated until a target platelet concentration of the blood is achieved.